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Although alopecia areata (AA) is not life threatening, it
may lead to severe psychological disturbances, redu-
cing the quality of life in all ages. Thus, a new animal
model is needed for shedding more light onto the
pathogenesis of this cell-mediated, organ-specific
autoimmune disease to identify more effective thera-
peutic strategies. Recently, we succeeded in develop-
ing a new humanized mouse model of AA, which
includes transplantation of healthy human scalp skin
obtained from normal volunteers on to severe-com-
bined immunodeficient mice. This is followed by
intradermal injection of either autologous or allo-
geneic peripheral blood mononuclear cells, which
had been cultured with high dose of IL-2 and enriched
for natural killer group 2D–positive (NKG2Dþ ) and
CD56þ cells. This protocol leads to rapid and pre-
dictable development of focal hair loss, with all the
characteristic clinical, histological, and immunohisto-
chemical features of AA. This humanized mouse AA
model underscores the functional importance of
NKG2Dþ and CD56þ cells in AA pathogenesis and
promises to be instrumental for identifying novel AA
treatment strategies.
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Although animal models are an important tool in the ongoing
challenge to understand the pathogenesis of various auto-
immune diseases, for many of these, optimal animal models
with sufficient relevance to the human condition remain to
be developed. Alopecia areata (AA) exemplifies this problem,
as the best-established mouse model (Sundberg et al., 1994)
of this CD8þ T cell–dependent, organ-specific autoimmune
disease (Bertolini et al., 2012; Gilhar et al., 2012a), whose
pathogenesis has not been fully resolved yet, and is not
entirely satisfactory.
For example, spontaneously occurring AA–like hair loss
develops only very late and rather unpredictably, and in a very
low percentage of mice; also, in the aging C3H/HeJ mouse
model of AA, the inflammatory infiltrate occurs in an untypical
perifollicular location; even though the occurrence of AA–like
lesions can be accelerated by transplantation of lesional skin
to as yet unaffected young mice (McElwee et al., 1998;
Freyschmidt-Paul et al., 2006), the problem remains that
C3H/HeJ mice display major constitutive immunological
abnormalities, such as a toll-like receptor-4 signaling defect
(e.g., Gosemann et al., 2010; Harlow et al., 2012) that is not a
feature of human AA. Disease onset, which is characterized
by—typically focal—loss of hair in any hair-bearing area
(Gilhar et al., 2012a)—is followed by an unpredictable
clinical course, and current treatment options are limited,
purely symptomatic, and overall unsatisfactory (Harries et al.,
2010; Gilhar et al., 2012a). Although the disease is not life
threatening, it may lead to severe psychological disturbances,
reducing the quality of life in patients of all age groups and
both genders (Inui et al., 2013), which is aggravated by the
lack of satisfactory therapy. While hair follicle immune
privilege collapse, CD8þ T cells, CD56þ natural killer
(NK) cells, and other natural killer group 2D-positive
(NKG2Dþ ) cell populations as well as IFN-g secretion by
these cells are all appreciated to have a key role in AA
pathogenesis (Paus et al., 2005; Freyschmidt-Paul et al., 2006;
Ito et al., 2008; Kang et al., 2010; Petukhova et al., 2010), the
exact pathogenesis of AA remains unknown (Bertolini et al.,
2012; Gilhar et al., 2012a).
Thus, a new, clinically relevant animal model is needed for
shedding more light on the pathogenesis of AA and as a
preclinical screening tool for probing novel, more effective
therapeutic strategies. Recently, we succeeded in developing
humanized mouse model that meets these aims (Gilhar et al.,
2012b). This model is based on three previous observations:
(1) AA can be transferred to human scalp skin transplants on
severe-combined immunodeficient (SCID) mice by injection
of lesional T cells, namely CD8þ lymphocytes, which had
been cultured with human hair follicle homogenate enriched
for melanocyte-related autoantigens (Gilhar et al., 2001). (2)
AA patients exhibit an overexpression of NK–activating recep-
tors (NKG2D) and NKG2D and their activating ligands (MICA,
ULBP3) (Ito et al., 2008; Petukhova et al., 2010). (3) The
NKG2D receptor, which is expressed by NK, NKT cells, and
subsets of other, mostly CD8þ , T cells is known to be
involved in the pathogenesis of some other autoimmune
diseases including diabetes mellitus and rheumatoid arthritis
(Gilhar et al., 2012a).
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In the new humanized AA mouse model, healthy human
scalp skin obtained from normal volunteers is transplanted
onto SCID mice, followed by intradermal injection of either
autologous or allogeneic peripheral blood mononuclear cells
(PBMCs). The PBMCs had been cultured with high dose of IL-2
before the injections into the grafts. Flow cytometric analysis
and in vitro study revealed that incubation of PBMCs with
high dose of IL-2 induced lymphocytes to express NK
phenotype, including high levels of NKG2D and CD56
(Gilhar et al., 2012b).
Injection of these NK–like cells into allogeneic or auto-
logous hair-bearing human skin grafts transplanted onto SCID
mice led to the rapid and predictable development of hair loss
lesions with all the characteristic clinical, histological, and
immunohistological features of human AA. Hair loss was
observed only in grafts injected with the NK–like cells 3–5
weeks following injections but not in the control groups.
(These controls included PBMCs cultured with phytohemag-
glutinin, which induces polyclonal PBMCs activation, instead
of high-dose IL-2 (PBMCs depleted of CD56þ cells; for
details, see Gilhar et al., 2012b)).
The humanized mouse model of AA permits the predictable
and rapid induction of a clinical, histological, and immuno-
histological phenocopy of human AA, notably in pre-
viously healthy human hair follicles within their natural
tissue habitat in vivo (albeit on immunocompromised
SCID mice). Moreover, this animal model is relatively easy
to setup as it requires only blood and scalp skin from
healthy volunteers, rather than from AA patients. Furthermore,
this novel animal model of human AA provides the
first functional evidence that NKG2Dþ cells as well as
NKG2D–stimulating ligands such as MICA and ULPB3
have a crucial role in primary AA pathogenesis (Ito et al.,
2008; Petukhova et al., 2010). In addition, as normal,
IL-2-stimulated PBMCs from healthy volunteers suffice to
induce an AA phenocopy, this questions how important
constitutive genetic abnormalities really are in primary AA
pathogenesis and refocuses attention on the secretory activities
of the (IFN-g-secreting) perifollicular infiltrate in AA (Gilhar
et al., 2012b).
Finally, and perhaps most importantly, this novel mouse
model provides an instructive new preclinical screening
device of unparalleled clinical relevance for exploring the
therapeutic effects of various candidates as future anti-AA
agents, and has already allowed us to identify Kv 1.3 blockers
as a promising novel class of candidate AA therapeutics
(Gilhar et al., 2013).
This new model also provides an intriguing opportunity to
instructively probe the effects of different types of stressors
leading to neurogenic skin inflammation (e.g., Arck et al.,
2006; Paus and Arck, 2009) on the development of AA.
Systematic use of this model is expected to quickly identify
additional new candidates, ideally including drugs that are
already in clinical use and could be easily repositioned for AA
management.
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